ENB Therapeutics is a clinical stage privately held company developing therapies to treat drug resistant cancers by reprogramming the tumor microenvironment. Our lead product, ENB-003, is a First-in-Class, small molecule, selective endothelin B receptor inhibitor that overcomes immunotherapy resistance across multiple cancer indications in preclinical studies. ENB-003 dramatically enhances anti-PD1 efficacy and when combined with CAR-T, eradicates most tumors within 3 weeks. In our ongoing international Phase 1 trial in collaboration with Merck, ENB-003, in combination with pembrolizumab, is well tolerated and demonstrates encouraging efficacy signals in drug refractory, heavily pre-treated pancreatic cancer, ovarian cancer and melanoma. ENB-003 is the key to unlocking new therapeutic markets in indications that do not respond to immunotherapies such as anti-PD1/PDL1, CTLA-4, CAR-T and cancer vaccines. To learn more, please visit www.enbpharma.com

We deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 4,100 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more. Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology. To learn more, visit https://www.10xgenomics.com/

Halloran is a life science consulting firm that provides strategic regulatory, quality, clinical, and organizational support to industry leaders and startup visionaries in the pharmaceutical, biotechnology, and med-device sectors. Our consultants are subject matter experts who deliver a tailored approach to each engagement, successfully propelling our clients to their next inflection point.To learn more, visit https://www.hallorancg.com/

A market leader in immuno-oncology imaging, we are focused on non-invasive, whole body, in vivo Immuno-PET imaging of CD8 T cells, using proprietary Minibody technology. By visualize the immune system’s response to therapy and tailoring immuno-oncology treatments our aim is to create a better way to prove cancer treatments work. 

Imaging Endpoints (IE) is the largest oncology-focused imaging CRO globally and is widely recognized for conducting the industry’s largest, most complex, and most successful imaging trials for both solid and liquid tumor indications. Additionally, IE is the global expert in CD8 PET imaging. IE is based in Scottsdale, AZ with offices around the world including Cambridge, MA; London, United Kingdom; Basel, Switzerland; Leiden, Netherlands; Hyderabad, India; and Shanghai, China. Learn more at www.imagingendpoints.com.

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. To learn more, visit www.isoplexis.com

Lupagen, Inc. is a privately held preclinical gene therapy company developing first-in-class gene delivery technologies for next generation CAR-T, gene editing and immunotherapy products based on its extracorporeal gene delivery platform. Lupagen’s platform harnesses standard apheresis-based systems customized for a diverse range of ex- vivo autologous cell and gene therapies that require targeted genetic or cellular modifications of targeted populations of a patient’s circulating peripheral blood mononuclear cells.

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. To learn more, please visit www.lunaphore.com

Lykan Bioscience is an innovative contract development and manufacturing services organization (CDMO) focused on cell-based therapies. With decades of biopharmaceutical industry experience, Lykan offers a full range of development and manufacturing services. The state-of-the-art, purpose-built facility offering eight independent manufacturing suites is uniquely designed to fully integrate cGMP principles and advanced software solutions to enable real-time testing and release of product. Six additional cGMP processing suites will be commissioned by the end of 2022 to support US/EU clinical and commercial manufacturing. Located in Hopkinton, Massachusetts, 25 miles southwest of downtown Boston and in the proximity of four international airports, Lykan Bioscience is ideally situated to deliver life-saving cell therapy treatments to patients on behalf of their partners. To learn more, please visit www.lykanbio.com

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions. The GeoMx® Digital Spatial Profiler combines the power of whole tissue imaging with gene expression and protein data. The CosMx™ Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution. To learn more, please visit www.nanostring.com

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Dive deeper at www.natera.com/oncology